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Abstract
Aims/hypothesis Bi-allelic loss-of-function mutations in the INSR gene (encoding the insulin receptor [INSR]) com-
monly cause extreme insulin resistance and early mortality. Therapeutic options are limited, but anti-INSR antibodies
have been shown to activate two mutant receptors, S323L and F382V. This study evaluates four well-characterised
murine anti-INSR monoclonal antibodies recognising distinct epitopes (83-7, 83-14, 18-44, 18-146) as surrogate
agonists for potential targeted treatment of severe insulin resistance arising from insulin receptoropathies.
Methods Ten naturally occurring mutant human INSRs with defects affecting different aspects of receptor function
were modelled and assessed for response to insulin and anti-INSR antibodies. A novel 3T3-L1 adipocyte model of
insulin receptoropathy was generated, permitting conditional knockdown of endogenous mouse Insr by lentiviral
expression of species-specific short hairpin (sh)RNAs with simultaneous expression of human mutant INSR
transgenes.
Results All expressed mutant INSR bound to all antibodies tested. Eight mutants showed antibody-induced autophos-
phorylation, while co-treatment with antibody and insulin increased maximal phosphorylation compared with insulin
alone. After knockdown of mouse Insr and expression of mutant INSR in 3T3-L1 adipocytes, two antibodies (83-7
and 83-14) activated signalling via protein kinase B (Akt) preferentially over signalling via extracellular signal-
regulated kinase 1/2 (ERK1/2) for seven mutants. These antibodies stimulated glucose uptake via P193L, S323L,
F382V and D707A mutant INSRs, with antibody response greater than insulin response for D707A.
Conclusions/interpretation Anti-INSR monoclonal antibodies can activate selected naturally occurring mutant human insulin
receptors, bringing closer the prospect of novel therapy for severe insulin resistance caused by recessive mutations.
Keywords Diabetes . Donohue syndrome . Insulin receptor . Insulin resistance . Insulin signalling . Monoclonal antibodies .
Rabson–Mendenhall syndrome
Abbreviations
3T3-L1 MmINSRKD Murine Insr-knockdown cells
AS160 Akt substrate of 160 kDa
CHO Chinese hamster ovary
DOX Doxycycline
ERK1/2 Extracellular signal-regulated
kinase 1/2
GSK3 Glycogen synthesis kinase 3
INSR Insulin receptor
MEK Mitogen-activated protein
kinase kinase
MOI Multiplicity of infection
p70S6K Ribosomal protein S6 kinase β-1
shRNA Short hairpin RNA
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Introduction
Insulin downregulates catabolic and activates anabolic path-
ways, suppresses apoptosis and promotes mitosis by activat-
ing a homodimeric receptor, tyrosine kinase [1, 2]. Human
loss-of-function mutations in the INSR gene, which encodes
the insulin receptor (INSR), were first reported in 1988 [3, 4].
Since then, more than 100 alleles causing severe insulin resis-
tance have been described [5]. Bi-allelic INSR mutations pro-
duce extreme insulin resistance, clinically described as
Donohue or Rabson–Mendenhall syndromes (OMIM
#246200 or #262190). These also feature impaired linear
growth and soft tissue overgrowth, with demise usually in
the first 3 years of life in Donohue syndrome.
Some INSR mutations impair receptor processing and cell
surface expression. Many mutations, however, are well
expressed, but exhibit impaired insulin binding, impaired sig-
nal transduction, perturbed recycling kinetics or a combina-
tion of these [6]. Proof that the signalling defect of such mu-
tant receptors might be circumvented by binding anti-receptor
antibodies was provided for two mutations, one in a cell cul-
ture model and one as solubilised receptor [7, 8].
Therapeutic antibodies are now well established both in
cancer, often blocking receptor signalling [9], and increasing-
ly for non-cancer indications [10]. Interest in biological ther-
apies targeting the INSR has recently rekindled, with inhibi-
tory antibodies in Phase 1 human trials [11] and stimulatory
antibodies shown to ameliorate diabetes in rodents [12–14]
and primates [15]. Given the high clinical need in recessive
insulin receptoropathy, we assessed the effect of monoclonal
anti-INSR antibodies [16–20] on a series of disease-causing
mutant INSRs.
Methods
Cell lines and culture conditions Culture media for Chinese
hamster ovary (CHO) Flp-In cells (Invitrogen, Carlsbad, CA,
USA) and 3T3-L1 pre-adipocytes (Zenbio, Raleigh, NC,
USA) are shown in electronic supplementary (ESM)
Table 1. Cell lines were all mycoplasma negative by PCR.
3T3-L1 pre-adipocytes were grown to confluence and differ-
entiation was induced by differentiation medium 1 for 72 h
then differentiation medium 2 for a further 72 h. Adipocytes
were maintained in adipocyte medium containing 1 μmol/l
insulin ±1 μg/ml doxycycline (DOX). Experiments were un-
dertaken at day 14 or 16 of differentiation.
hINSR mutant expression constructs and generation of CHO
Flp-In hINSR cellsMutation numbering refers to mature hINSR
ex11+ (GenBank M1005.1), which was amplified from
pDNR-Dual (Clontech, Mountain View, CA, USA) using
primers incorporating a C-terminus myc-tag. Sub-cloning is
detailed in ESM Table 2. Mutations were generated with the
Quickchange II XL kit (Stratagene, La Jolla, CA, USA). CHO
Flp-In cells were transfected with pCDNA5/FRT/TO/hINSR
and pOG44 using Lipofectamine 2000 (Invitrogen). The pop-
ulation surviving hygromycin B was used for experiments.
Lentivirus production and infection of 3T3-L1 pre-adipocytes
Target sequences, primers, vectors and sub-cloning steps are
detailed in ESM Table 3. Virus was packaged and concentrat-
ed as described by Shin et al [21]. 3T3-L1 pre-adipocytes were
•
•
•
•
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infected with the lowest multiplicity of infection (MOI) of
virus needed to confer hygromycin B resistance. Several
clones per line were characterised for endogenous Insr knock-
down and adipocyte differentiation by Oil Red O staining
[22]. For hINSR re-expression studies, 3T3-L1 murine Insr-
knockdown (MmINSRKD) cells were infected with virus
containing myc-tagged hINSR transgenes at the lowest MOI
needed to confer G418 resistance to generate polyclonal pop-
ulations. hINSR expression was confirmed by cDNA
sequencing.
Flow cytometry CHO Flp-In hINSR cells were blocked by 5%
(vol./vol.) FCS/FACS buffer (ESM Table 4) before incubation
with primary antibodies for 1 h at 4°C. Bound antibodies were
detected using FITC-conjugated anti-mouse IgG and a BD
FACSCalibur Flow Cytometer (530 nm/30 nm bandwidth fil-
ter, Becton Dickinson, Franklin Lakes, NJ, USA). Stacked
histograms were visualised with FCS Express 6 Plus
(DeNovo Software, Glendale, CA, USA).
Receptor autophosphorylation assays CHO Flp-In hINSR
cells were washed twice and serum starved (16 h) before stim-
ulation with insulin, antibody or both for 10 min at 37°C/5%
CO2 and lysed on ice in lysis buffer (ESM Table 4). Receptors
were captured overnight at 4°C on anti-myc antibody 9E10-
coated white Greiner Lumitrac 600 96 well plates.
Phosphotyrosines on immunocaptured receptors were detect-
ed with biotin-conjugated 4G10 platinum phospho-tyrosine
antibody and europium-labelled streptavidin. DELFIA en-
hancement solution was added and time-resolved fluores-
cence measured (excitation 340 nm/emission 615 nm).
Downstream signal activation 3T3-L1 adipocytes were
washed twice in DMEM, serum starved for 16 h in
DMEM/0.5% BSA/1 μg/ml DOX and treated for 10 min at
37°C/5% CO2 with 10 nmol/l insulin, 10 nmol/l antibody or
both in DMEM/0.5% (wt/vol.) BSA. Cells were washed, snap
frozen and lysed on ice before centrifugation twice at 4°C for
15 min to pellet insoluble material and separate lipids prior to
western blotting.
Western blotting Lysate, 10 μg, was resolved on NuPAGE 4–
12% bis-tris gels or E-PAGE 48 8% gels (Life Technologies,
Carlsbad, CA, USA) and transferred to nitrocellulose by iBlot
(Life Technologies). Membranes were blocked in 3% BSA
(wt/vol.)/tris-buffered saline with Tween 20 (TBST) before
overnight incubation at 4°C with primary antibodies (ESM
Table 5). Horseradish peroxidase (HRP)-conjugated second-
ary antibodies and Immobilon Western Chemiluminescent
HRP substrate (Millipore, Darmstadt, Germany) were used
to detect protein–antibody complexes, and grey-scale 16 bit
tag image file formats (TIFFs) captured with an ImageQuant
LAS4000 camera system (GE Healthcare Lifesciences,
Marlborough, MA, USA). Each immunoblot in Fig. 4 and
ESM Fig. 2 contained a sample of 3T3-L1 MmINSRKD
hINSR wild type (WT) treated with 10 nmol/l insulin.
Western blot image densitometry Pixel density of grey-scale
16 bit TIFFs was determined in ImageJ 1.47v (NIH, Bethesda,
MD, USA). The rectangle tool was used to select lanes and the
line tool to enclose the peak of interest and subtract back-
ground. The magic-wand tool was used to select the peak area
and obtain the raw densitometry value. Mean band intensities
of total INSRβ, myc-tagged INSRβ, Akt, extracellular signal-
regulated kinase 1/2 (ERK1/2), glycogen synthase kinase 3
(GSK3)α/β, ribosomal protein S6 kinase β 1 (p70S6K) and
calnexin were used to normalise raw densitometry values for
p-INSRβ, p-Akt, p-ERK1/2, p-GSK3α, p-p70S6K and p-Akt
substrate of 160 kDa (p-AS160). Normalised values for phos-
phorylated targets were scaled to the meanWT INSR response
to insulin.
Glucose uptake 3T3-L1 adipocytes were washed twice
(DMEM), serum starved for 16 h in low-glucose
DMEM/0.2% BSA/1 μg/ml DOX, washed twice in PBS and
then stimulated for 30 min at 37°C/5% CO2 with 10 nmol/l
insulin, 10 nmol/l antibody or both in KRPH/0.2% BSA buff-
er (ESM Table 4). Cells were incubated with 1 mmol/l 2-
deoxy-D-glucose for 5 min at 37°C/5% CO2 before washing
(PBS), lysing with 0.1 mol/l NaOH, and snap freezing.
Glucose uptake was measured by the fluorescence method
of Yamamoto et al [23].
Statistical analysis One-way ANOVAs with Tukey’s multiple
comparisons test were performed with GraphPad Prism 6
(GraphPad software, San Diego, CA, USA). Error bars repre-
sent SEM or SD as indicated. All experiments were performed
at least three times.
Results
Assessment of mutant INSR cell surface expression and anti-
body binding Eleven INSR mutations were selected for
study (ESM Table 6). Eight were chosen based on evi-
dence of cell surface expression, prioritising mutations
identified in multiple reports to maximise potential avail-
ability of participants for future trials. A previously un-
published mutation, F248C, that we identified in a child
with Rabson–Mendenhall syndrome, was included oppor-
tunistically. The well-studied P1178L tyrosine kinase mu-
tation [24, 25] and the L62P mutation, which severely
impairs processing [26], were added as controls.
Figure 1a displays the extracellular INSR mutations
mapped onto the crystal structure of the INSR [27].
Four mouse monoclonal anti-human INSR antibodies
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were used, which had all previously been shown to have
partial agonist activity at WT receptors, but different ef-
fects on kinetics and affinity of insulin binding (Table 1).
As Fab fragments of 83-7 and 83-14 were used in deter-
mining the crystal structure of insulin-bound INSR [28],
their binding epitopes are known (Fig. 1b).
Mutations were introduced into the B isoform of the INSR,
believed to be the more important isoform for the metabolic
actions of insulin [29]. To enable discrimination of endoge-
nous INSR and human INSR mutants, a C-terminal myc-tag
was used in the mutant constructs. Tagged mutants were
expressed in CHO cells using the Flp-In system, ensuring
differences in protein expression are due to differential pro-
cessing or stability of receptor protein rather than differential
mRNA expression. The mutants were well processed to ma-
ture β subunits, with the exception of L62P, for which β
subunit was barely detectable. More modest reductions were
seen for the previously unstudied F248C and for the P1178L
mutation (Fig. 1c).
Cell surface expression and antibody binding of mutant
INSR was assessed by flow cytometry (Fig. 1d–g). All
INSR antibodies bound each mutant INSR, as shown by
right-shifted peaks relative to control IgG, indicating no gross
changes in receptor morphology. Poor expression of L62P
was in keeping with prior reports [30], and L62P was not
studied further. The rightward shift for mutants corresponded
to expression of mature β subunits seen by immunoblotting,
suggesting that relative shifts reflected differences in receptor
expression rather than antibody affinities. Although some mu-
tations are close to the epitope for antibody 83-7, none of the
affected residues provides critical antibody contacts. Indeed,
no difference in binding of 83-7 (Fig. 1d) to the mutant panel
was seen compared with 83-14 (Fig. 1e), which binds to a
surface unaffected by the mutations (Fig. 1a, b). Antibody
83-7 demonstrated cross-reactivity with endogenous CHO
INSR, as evidenced by positive staining of CHO Flp-In parent
cells, while the other antibodies did not detectably cross-react.
Assessment of mutant INSR autophosphorylation in response
to antibody and/or insulin Trans-autophosphorylation of ty-
rosines in the intracellular INSR is the first detectable signal-
ling event after insulin binding, so the ability of insulin and
antibodies to induce tyrosine phosphorylation of mutant INSR
was next examined using anti-myc immunoprecipitation and
europium-based immunoassay. Most mutant receptors
(P193L, F248C, R252C, S323L, F382V, D707A, P1178L)
demonstrated diminished maximal autophosphorylation re-
sponse to insulin, ranging from 0 to 27% WT (Fig. 2a–j,
Table 2, data not shown for non-responsive P1178L).
However, R118C, I119M and K460E showed autophosphor-
ylation comparable with WT, and so were not studied further.
Altered insulin EC50 was discernible only for S323L
(Table 2), although the insulin concentration range tested
and the small magnitude of responses precluded precise
determinations.
Antibodies 83-7 and 83-14 alone also elicited autophos-
phorylation of WT and all mutant INSRs except F248C and
P1178L. In most instances, antibody response was lower than
insulin response (Fig. 2a–j, Table 2); however, for S323L the
Fig. 1 Mutant INSR is expressed at the cell surface and bound by anti-
INSR antibody. (a) INSR monomer Protein Data Bank (PDB) structure
entry 4ZXB [22] visualised with CCP4MG (v. 2.10.6); locations of mu-
tated residues (this study) are highlighted in red. (b) INSR monomer in
complex with Fab fragments 83-7 and 83-14, PDB structure 4ZXB [22].
(c) Western blot of lysates from CHO Flp-In cells stably expressing hu-
man WT or mutant INSR, as indicated. In INSRβ subunit and myc-tag
blots, upper bands are pro-INSR and lower bands are mature processed β
subunits, as indicated. (d–g) Stacked overlay single parameter histograms
showing cell surface expression of INSR mutants bound by antibodies
83-7 (d), 83-14 (e), 18-44 (f) and 18-146 (g), as determined by flow
cytometry. Intensity of INSR-FITC fluorescence is shown on the x-axis
and the peak height indicates relative number of events. Isotype control
IgG (light grey) was used as a negative control to generate a negative gate
to determine the percentage of the population positive for anti-INSR
antibody binding. Rightward shift of the peak (blue 83-7, cyan 83-14,
orange 18-44, purple 18-146) from the IgG control is a function of both
mutant INSR expression and antibody affinity. Pos, positive
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maximal autophosphorylation response to 83-7 and 83-14 was
similar to that with insulin (Fig. 2g), while D707A was acti-
vated by antibodies but not insulin (Fig. 2j).
We next evaluated responses to insulin +10 nmol/l anti-
body, based on evidence that this concentration elicits the
maximal response [18, 20]. In the presence of antibodies 83-
7 and 83-14, the maximal response of WT and mutant INSRs
to insulin was increased without affecting potency (although
EC50 values were not precisely determined) (Fig. 2k–t,
Table 2). This was observed across all mutant receptors except
the kinase-dead P1178L [24, 25]. Antibodies 18-44 and 18-
146 elicited smaller effects than 83-7 and 83-14, and for clar-
ity of presentation data for these antibodies are shown in the
ESM (ESM Results, ESM Figs 1, 2, ESM Table 7).
Generation of a novel adipocyte cell model of insulin
receptoropathy To assess antibody-induced signalling down-
stream from the INSR, an adipocyte model of insulin
receptoropathy was generated. A tetracycline (tet)-responsive
microRNA (miR)-short hairpin (sh)RNA selectively targeting
murine Insr was transduced into 3T3-L1 pre-adipocytes to
generate a stable clone (Fig. 3a). This was transduced with
lentiviruses encoding C-terminal myc-tagged WT or mutant
hINSR, also controlled by tet-responsive elements (Fig. 3b),
generating cells in which DOX simultaneously knocked down
endogenous murine Insr and induced overexpression of myc-
tagged human INSR. This system permitted pre-adipocyte
differentiation uncompromised by mutant receptor expression
before induction of Insr knockdown/hINSR re-expression in
adipocytes (Fig. 3c, d). The DOX concentration producing
maximal Insr knockdown resulted in overexpression of
hINSR transgenes (Fig. 3c, e); however, the receptor-
processing defects observed in CHO cells (Fig. 1c) were pre-
served. The C-terminal myc-tag enabled discrimination of en-
dogenous mouse and ectopic human INSR by size shift of the
INSR β subunit on immunoblotting, or by anti-myc antibod-
ies (Fig. 3e). The pre-adipocyte cell lines generated differen-
tiated efficiently into mature adipocytes, as evidenced by Oil
Red O staining (Fig. 3f).
Activation of signalling downstream from mutant INSRs by
insulin and antibody Plasma insulin concentration in human
insulin receptoropathies lies between 0.3 and 3 nmol/l in the
fasting state (ESM Table 6), and at least an order of magnitude
higher when fed. We used an insulin concentration of
10 nmol/l, mimicking the fed disease state. WT INSR auto-
phosphorylation was strongly induced by insulin (Fig. 4a, b),
but was undetectable after receptor knockdown alone (ESM
Fig. 2c, d). Otherwise, the pattern of autophosphorylation of
overexpressed receptors in response to insulin and/or antibody
was similar to that seen in CHO cells. Thus, antibodies 83-7
and 83-14 alone inducedWT receptor autophosphorylation on
Y1162/Y1163, while antibodies 18-44 and 18-146 were less
effective (ESM Fig. 2, ESM Results). Insulin-stimulated auto-
phosphorylation was reduced by 75-100% in mutant INSRs
compared with WT. Although antibodies alone induced low-
level phosphorylation of mutant INSRs (<10%), the responses
of S323L and D707A to antibodies 83-7 and 83-14 were equal
to or greater than those to insulin (Fig. 4g–j). Combined insu-
lin and antibody treatment enhanced phosphorylation of each
Table 1 Characteristics of INSR antibodies studied
Characteristic Antibody
83-7 83-14 18-44 18-146
Type Mm mAb IgG1
(bivalent) [17]
Mm mAb IgG2a
(bivalent) [17]
Mm mAb IgG2b
(bivalent) [17]
Mm mAb IgG1
(bivalent) [17]
Epitope CR domaina [28] Fn1 domaina [28] Within extracellular
β subunit [17]
Within α subunit
Effect on INSR
Insulin binding Modestly enhances [17, 19] Inhibits [17] Modestly inhibits [17] Enhances [17]
Pre-bound insulin No effect on
dissociation [18]
Inhibits
dissociation [18]
No effect on
dissociation [18]
Inhibits
dissociation [18]
Autophosphorylation Stimulates [19] Stimulates [16] Stimulates [19] Not assessed
Kinase activity Stimulates [18, 19] Stimulates [18, 19] Stimulates [18, 19] Stimulates [18]
Biological outcomes
Glucose uptake Stimulates [16] Stimulates [16] Stimulates [16] Not assessed
Lipogenesis Stimulates [20] Stimulates [20] Stimulates [20] Not assessed
Type, epitope and effect onWT INSR insulin binding, pre-bound insulin, autophosphorylation, kinase activity, glucose uptake and lipogenesis of murine
monoclonal antibodies used throughout this study
a Precise epitope known
CR, cysteine-rich domain; Fn1 , first fibronectin type III domain; mAb, monoclonal antibody; Mm, murine
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mutant INSR in the case of 83-7 and 83-14, likely synergisti-
cally (Fig. 4, ESM Fig. 2).
Akt2/PKBβ transduces metabolic actions of insulin after
phosphorylation of T308 and S473. p-Akt2 phosphorylates
substrates including glycogen synthase kinase (GSK3α/β),
which regulates glycogen synthesis, p70 S6 kinase
(p70S6K), which stimulates protein synthesis, and AS160,
which encodes a GTPase-activating protein that restrains
Fig. 2 Insulin- and antibody-stimulated autophosphorylation of WT
and mutant INSR. CHO Flp-In cells stably expressing either human
WT or mutant INSR (as indicated) were serum starved prior to 10 min
stimulation with increasing concentrations of insulin, antibody (83-7, 83-
14) or control IgG (black lines), or increasing concentrations of insulin in
the presence of 10 nmol/l antibody (grey lines). Cells were lysed and
myc-tagged receptors were immunocaptured on 96 well plates and then
incubated with biotin-conjugated 4G10 platinum antibody to detect phos-
phorylated tyrosine residues. Europium-labelled streptavidin was used to
detect bound anti-phosphotyrosine antibody 4G10 by time-resolved
fluorescence. The data points are the mean ± SEM of duplicate samples
from three independent experiments and plotted on a log10 scale for the x-
axis. Error bars are shown when larger than size of the symbols. In (a–j),
single treatments are shown as follows: black circles (solid line), insulin;
black up-pointing triangle (dashed line), 83-7; black down-pointing tri-
angle (dotted line), 83-14; black open circles (solid line), control IgG. In
(k–t), dual treatments are denoted by: grey up-pointing triangle (dashed
line), insulin +10 nmol/l 83-7; grey down-pointing triangle (dotted line),
insulin +10 nmol/l 83-14; grey circles (dotted/dashed line), insulin
+10 nmol/l control IgG. pEC50 values are presented in Table 2
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Table 2 Autophosphorylation of WT and mutant INSR stimulated by insulin, antibody or insulin +10 nmol/l antibody
INSR/stimulation Insulin 83-7 83-14 IgG Insulin + 83-7 Insulin + 83-14 Insulin + IgG
WT
EC50 (nmol/l) 0.3 3.0 – – 1.8 2.3 3.4
pEC50 9.5 8.5 – – 8.7 8.6 8.5
95% CI 9.7, 9.4 9.1, 7.9 – – 8.9, 8.5 8.8, 8.5 9.0, 7.9
Emax (% Ins) 100 11 12 0 142 158 64
R118C
EC50 (nmol/l) 1.4 13.2 2.6 – 1.0 1.3 1.4
pEC50 8.9 7.9 8.6 – 9.0 8.9 8.9
95% CI 9.1, 8.6 8.1, 7.6 9.0, 8.1 – 9.2, 8.8 9.1, 8.6 9.1, 8.6
Emax (% Ins) 100 26 26 1 131 160 94
Emax (% WT Ins) 65 17 17 0 85 104 61
I119M
EC50 (nmol/l) 2.6 >25 >23 – 2.8 3.5 3.1
pEC50 8.6 >7.5 >7.6 – 8.6 8.5 8.5
95% CI 8.9, 8.3 – – – 8.7, 8.4 8.6, 8.3 8.8, 8.2
Emax (% Ins) 100 14 27 1 128 152 93
Emax (% WT Ins) 99 14 27 1 127 150 92
P193L
EC50 (nmol/l) 1.4 >193 3.2 – 1.4 1.8 1.2
pEC50 8.9 >6.7 8.5 – 8.9 8.7 8.9
95% CI 9.1, 8.7 – 9.6, 7.3 – 9.0, 8.7 9.0, 8.5 9.1, 8.5
Emax (% Ins) 100 17 20 1 173 217 91
Emax (% WT Ins) 23 4 5 0 40 50 21
F248C
EC50 (nmol/l) 0.4 – – – 0.3 3.2 1.8
pEC50 >7.2 – – – 9.5 8.5 8.7
95% CI 9.8, 9.0 – – – 10.0, 9.1 9.0, 8.0 9.9, 7.6
Emax (% Ins) 100 0 12 5 243 287 75
Emax (% WT Ins) 3 0 0 1 7 8 2
R252C
EC50 (nmol/l) 2.2 – – – 1.6 1.8 1.7
pEC50 8.6 – – – 8.8 8.7 8.8
95% CI 9.0, 8.3 – – – 9.2, 8.4 9.3, 8.2 9.1, 8.4
Emax (% Ins) 100 15 15 1 141 166 85
Emax (% WT Ins) 27 4 4 0 38 45 23
S323L
EC50 (nmol/l) >58 18.6 3.9 – 36.4 22.4 >97
pEC50 >7.2 7.7 8.4 – 7.4 7.6 >7.0
95% CI – 8.9, 6.5 8.8, 8.0 – 7.8, 7.1 7.9, 7.4 –
Emax (% Ins) 100 79 102 2 566 855 122
Emax (% WT Ins) 9 7 9 0 51 77 11
F382V
EC50 (nmol/l) 1.8 12.3 – – 1.6 1.6 1.5
pEC50 8.7 7.9 – – 8.8 8.8 8.8
95% CI 9.0, 8.5 8.6, 7.2 – – 9.2, 8.4 9.2, 8.4 9.6, 8.0
Emax (% Ins) 100 10 10 5 152 184 84
Emax (% WT Ins) 19 2 2 1 29 35 16
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GLUT4 vesicle translocation until phosphorylated. Insulin
treatment of WT INSR induced strong Akt phosphorylation
at both sites (Fig. 4a, b), and this was severely attenuated by
knockdown of endogenous Insr or by knockdown with re-
expression of the kinase-dead P1178L mutant (Fig. 4k, l).
Attenuation of signalling was also apparent downstream of
Akt, with phosphorylation of p70S6K and GSK3 only mod-
estly impaired, and AS160 phosphorylation unaffected.
Several patterns were seen across the panel of mutants
studied. In D707A receptor-expressing cells (Fig. 4i, j),
insulin-induced phosphorylation of Akt and its substrates
was severely attenuated, while a progressive ‘escape’ from
signalling impairment was seen in mutants S323L (Fig. 4g,
h), F248C (ESM Fig. 2g, h) and F382V (ESM Fig. 2m, n),
with lesser impairment of Akt phosphorylation than of recep-
tor autophosphorylation, and only partial inhibition at down-
stream substrates. P193L (Fig. 4c, d) and R252C (Fig. 4e, f)
demonstrated similar insulin-induced Akt and Akt substrate
phosphorylation to WT receptor.
Antibodies alone stimulated Akt and Akt substrate phosphor-
ylation in all cells except those overexpressing the kinase-dead
P1178L mutant (Fig. 4k, l). For S323L and D707A mutants,
antibodies 83-7 and 83-14 stimulated greater phosphorylation
than insulin alone, by virtue of the low response of those mu-
tants to insulin (Fig. 4g–j). Co-treatment of cells with insulin and
antibodies 83-7 and 83-14 enhanced Akt and Akt substrate
phosphorylation with respect to insulin alone, without evidence
of synergy. The additive effects of insulin and antibody co-
stimulation were generally less than those observed for receptor
autophosphorylation in CHO cells (Fig. 2k–t).
Activation of the INSR by insulin stimulates not only
phosphoinositide 3-kinase (PI3K)/Akt, but also RAS/RAF/
mitogen-activated protein kinase kinase (MEK)/ERK signal-
ling, through both IRS-dependent and IRS-independent mech-
anisms [31]. Activation of this pathway is a surrogate for
mitogenicity of insulin analogues [32], which is important in
view of concerns about long-term cancer risks of analogues
with pro-proliferative activity. Insulin treatment of WT INSR
induced robust phosphorylation of ERK1/2 at Y204/Y187,
with each mutant INSR displaying reduced phosphorylation
in response to insulin compared with WT (Fig. 4). Antibody
treatment of mutant or WT INSR did not induce ERK1/2
phosphorylation, while dual stimulation with antibody + insu-
lin did not increase ERK1/2 phosphorylation compared with
insulin alone. Higher basal ERK1/2 phosphorylation was ob-
served in cells with Insr knockdown alone (ESM Fig. 2c, d),
or with Insr knockdown and P1178L receptor overexpression
(Fig. 4k, l), but this did not change with any treatment.
Effect of insulin and/or antibody on glucose uptake Glucose
uptake is a key outcome of INSR activation and was assessed
in the 3T3-L1 model. Parent 3T3-L1 cells and cells
harbouring the Insr-knockdown construct but not treated with
DOX displayed similar high levels of insulin-stimulated glu-
cose uptake (ESM Fig. 3a, b), but insulin did not stimulate
uptake in conditional Insr-knockdown cells treated with doxy-
cycline (Fig. 5i). Cells with endogenous mouse Insr knock-
down andWT hINSR re-expression, in contrast, demonstrated
only a 1.8-fold increase in glucose uptake on insulin stimula-
tion (ESM Fig. 3a). The apparently poor response to insulin
was due to increased basal glucose uptake in WT receptor-
overexpressing cells (ESM Fig. 3b). Basal uptake among mu-
tant receptor-expressing cell lines reflected mutant receptor
function (ESM Fig. 3c).
Table 2 (continued)
INSR/stimulation Insulin 83-7 83-14 IgG Insulin + 83-7 Insulin + 83-14 Insulin + IgG
K460E
EC50 (nmol/l) 1.9 25.2 5.7 – 1.7 1.8 2.2
pEC50 8.7 7.6 8.2 – 8.8 8.7 8.7
95% CI 9.1, 8.4 7.8, 7.2 8.5, 7.9 – 8.8, 8.7 8.9, 8.6 8.8, 8.5
Emax (% Ins) 100 31 29 1 129 152 100
Emax (% WT Ins) 96 30 28 1 124 146 96
D707A
EC50 (nmol/l) – >24 3.6 – – – –
pEC50 – >7.6 8.4 – – – –
95% CI – – 8.6, 8.2 – – – –
Emax (% Ins) 100 4016 5383 416 7793 8230 1270
Emax (% WT Ins) 0 8 11 1 15 16 2
EC50, half-maximal effective concentration in nmol/l; pEC50, negative log of EC50 half-maximal effective concentration value in mol/l; 95% CI, 95%CI
for pEC50; Emax, maximum efficacy expressed as a % of a particular receptor response to insulin (% Ins) or as %WT receptor response to insulin (%WT
Ins); Ins, insulin; −, not able to be determined
Diabetologia
Despite reduced dynamic range in the assay, insulin
stimulated glucose uptake via WT, P193L, F248C, R252C and
F382Vreceptors (Fig. 5a, b, d, f, respectively). Insulin-stimulated
uptake was similar in cells expressing P193L, R252C or F382V
receptor and those expressing WT receptor, but was reduced in
cells expressing the F248C mutant. No stimulation of glucose
uptake was seen in cells expressing S323L, D707A or P1178L
receptors (Fig. 5e, g, h, respectively).
Antibodies 83-7 and 83-14 alone stimulated glucose uptake
via P193L, S323L, F382Vand D707A receptors (Fig. 5), while
antibodies 18-44 and 18-146 were again less effective across the
full range of mutants (ESM Fig. 4). While the magnitude of
antibody-stimulated uptake was less than that seen with insulin
viaWT, P193L, F248C, R252C and F382Vreceptors, antibodies
83-7, 83-14 and 18-44 were more effective than insulin at stim-
ulating glucose uptake via D707A. Dual treatment with
antibodies + insulin did not enhance glucose uptake compared
with insulin alone acting via WT, P193L, F248C, R252C and
F382V receptors, or antibody alone when acting via S323L and
D707A receptors.
Discussion
Recessive insulin receptoropathies feature failure to thrive,
extreme metabolic derangement, childhood mortality and
poor response to therapy. Longitudinal studies suggest a steep
relationship between residual INSR function and clinical out-
come: loss of 50% INSR function, as in the parents of infants
with Donohue syndrome, does not produce insulin resistance
in lean people. Heterozygous dominant negative mutations
produce severe insulin resistance, diagnosed peripubertally
Fig. 3 Generation of a novel stable 3T3-L1 adipocyte model of insulin
receptoropathy. (a) Concatenated miR-shRNAs targeting murine Insr in
exon 2 and exon 9 preceded by GFP under the control of a tet-responsive
element was packaged into third-generation lentivirus to enable transduc-
tion of 3T3-L1 pre-adipocytes. The exploded view shows the nucleotide
mismatches between the mouse Insr targeted by each miR-shRNAwith
the human INSR sequence. Green shaded elements of the transgene are
inducible by the addition of DOX. Transduced 3T3-L1 pre-adipocytes
underwent single cell clonal selection in the presence of hygromycin to
generate 3T3-L1 MmINSRKD. (b) 3T3-L1MmINSRKD cells were then
transduced with a second lentivirus encoding C-terminal myc-tagged hu-
man INSR transgenes under the control of a tet-responsive element and
underwent polyclonal selection in the presence of neomycin to generate
3T3-L1MmINSRKD hINSR. (c)Western blots of whole-cell lysates from
day 10 mature 3T3-L1 MmINSRKD and 3T3-L1 MmINSRKD hINSR
WTcells grown in the presence of increasing concentrations of DOX for
72 h. (d) Densitometry analysis of western blots from three independent
experiments demonstrating knockdown of endogenous mouse Insr and
expression of human INSR with increasing concentrations of DOX. (e)
Western blots of whole-cell lysates from day 16 mature 3T3-L1
MmINSRKD and 3T3-L1MmINSRKD hINSR (mutant INSR as indicat-
ed) cells grown in the presence of 1μg/ml DOX for 10 days. (f) Oil Red O
staining of lipid accumulation in day 10 mature 3T3-L1 MmINSRKD
and 3T3-L1MmINSRKD hINSRWTormutant (as indicated) cells grown
± DOX (1 μg/ml) for 72 h. GFP, green fluorescent protein; Hygro,
hygromycin resistance; IRES, internal ribosome entry site; Mm, murine;
Neo, neomycin resistance; rtTA3, reverse tetracycline-controlled
transactivator; TRE, tet-response element; Ubi-C, ubiquitin C promoter
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in girls and later in men, and reduce receptor function to 25%
or less of WT. The severe recessive receptoropathies that this
study focuses on confer greater loss of function. However,
even with 0–25% residual function, a range of phenotypes is
seen, with complete loss of function producing Donohue syn-
drome and lethality in infancy, but less extreme loss of func-
tion producing Rabson–Mendenhall syndrome, with survival
to the second or third decade. These observations suggest that
even modest improvements in receptor signalling in recessive
disease may have decisive clinical benefit.
Many pathogenic INSRmutations are known, including more
than 100 missense mutations. A subset are expressed at the cell
surface, but show impaired insulin binding, signal transduction
or internalisation and recycling. This subset may be amenable to
non-conventional activation by antibody. Proof of this principle
came from demonstration that two bivalent antibodies stimulated
kinase activity of a single solubilised mutant receptor (F382V
[7]), and, independently, that one bivalent antibody increased
glycogen synthesis acting via a mutant receptor expressed in
intact cells (S232L [8]).We extend these findingswith systematic
characterisation of multiple receptor mutants and antibodies in
two cellular systems, assaying physiologically important re-
sponses including adipocyte glucose uptake.
One of the mutants assessed, F248C, is novel. It lies close
to the R252C mutant, which is expressed but exhibits im-
paired internalisation after insulin exposure [33]. F248C
shows minor reduction in cell surface expression, but
insulin-stimulated receptor autophosphorylation and down-
stream signalling are severely impaired. Across known mu-
tants, our data generally agree with prior studies. Assay of
receptor autophosphorylation in CHO cells using
immunocapture of myc-tagged receptor prior to immunoassay
demonstrated signalling defects more clearly than
phosphotyrosine immunoblotting in the 3T3-L1 overexpres-
sion system, likely reflecting the inherently greater dynamic
range of immunoassay allied to use of a generic anti-
phosphotyrosine antibody.
We confirmed that S323L and F382V receptors can be acti-
vated by antibodies and extended these observations to a wider
range of mutants. Previous studies suggest that receptor activa-
tion by antibody depends on receptor cross-linking rather than
reaction at specific epitopes [19]. Consistent with this, two of the
antibodies we employed, 83-7 and 83-14, are both effective de-
spite recognising different epitopes and having different effects
on insulin binding. Antibodies 18-44 and 18-146 consistently
elicited much smaller responses, although 18-44 has previously
been found to exert insulin-like activity on primary human adi-
pocytes [20]. Differences among antibodies are likely to reflect
differences of affinity and/or steric constraints on cross-linking
receptors.
The mutants showing the largest antibody response were
S323L and D707A, both being activated by antibodies simi-
larly to WT receptor, and to a greater extent than by insulin.
Such mutants with ‘pure’ insulin-binding defects are particu-
larly attractive therapeutic targets. Other mutants studied in
both cell systems (P193L, F248C, R252C and F382V)
showed some activation of Akt, GSK3, AS160 and glucose
uptake by antibodies. In these cases, responses were less than
for WT receptor or those induced by insulin. Testing the ther-
apeutic potential of antibodies against such mutants is war-
ranted in vivo, where antibody signalling may be prolonged
compared with insulin signalling because of slower receptor
internalisation. Indeed, a previously studied anti-INSR anti-
body showed markedly greater hypoglycaemic effects in vivo
in WT animals than had been apparent in cell culture models
[13].
Antibodies would be a particularly appealing therapeutic
proposition were they to exhibit synergy with insulin in receptor
stimulation, amplifying insulin action rather than simply impos-
ing a tonic signal. The current studies have not addressed this in
detail, although suggestive evidence for synergic stimulation of
WT receptor and some mutant receptors is seen. This was not
mirrored by detectable synergistic activation of downstream sig-
nalling or metabolic endpoints, possibly becausemaximal down-
stream signalling requires only submaximal receptor autophos-
phorylation. It remains possible that insulin–antibody synergy
does exist but was obscured under the conditions of the experi-
ments undertaken, which pragmatically employed relatively high
concentrations of insulin and antibody.
Early cellular studies of antibody-induced INSR activation
were interpreted as suggesting that antibodies elicit greater
downstream responses than expected from low levels of re-
ceptor autophosphorylation [16, 34–36]. These observations
were later argued to have a methodological basis, hinging on
lower sensitivity in detecting tyrosine phosphorylation than
downstream signalling [37, 38]. This is, in part, because signal
amplification is an inherent property of signal transduction
cascades. Our observation of apparent ‘escape’ from signal-
ling inhibition in the face of efficient Insr knockdown in 3T3-
L1 adipocytes supports this contention, as activation of
Fig. 4 Activation of signalling pathways downstream of WT and mutant
INSR by insulin and antibody stimulation. 3T3-L1 MmINSRKD hINSR
WT (a, b), P193L (c, d), R252C (e, f), S323L (g, h), D707A (i, j) and
P1178L (k, l) adipocytes were grown in the presence of 1 μg/ml DOX for
8 days prior to overnight serum starvation on day 13 of differentiation.
Adipocytes were then stimulated with either 10 nmol/l insulin (red bars),
10 nmol/l antibody (83-7, 83-14 or control IgG; dark grey bars) or
10 nmol/l insulin containing 10 nmol/l antibody (light grey bars) for
10 min at 37°C/5% CO2. Following stimulation, cells were washed and
snap frozen prior to lysis and western blot. Bar graphs show p-INSRβ, p-
ERK1/2, p-Akt, p-GSK3α, p-p70S6K and p-AS160 densitometry after
normalisation for each sample by the sum aggregate of multiple proteins
(total INSRβ, myc-tagged INSRβ, ERK1/2, Akt, GSK3α/β, p70S6K
and calnexin) for each biological replicate. Data are the mean ± SD of
three independent experiments and are expressed relative to hINSRWT
response to insulin stimulation; individual data points are shown in scatter
plots. For clarity of presentation, only key data are presented here; an
extended version appears as ESM Fig. 2
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residual receptors is undetectable directly but is observable
downstream, owing to signal amplification.
Importantly, receptor activation by antibodies leads to
selective Akt phosphorylation, which is critical for meta-
bolic actions of insulin, with little or no ERK phosphory-
lation. As activation of the RAS/RAF/MEK/ERK pathway
is mitogenic, this is an encouraging property of antibodies
for translational purposes, suggesting that they may exert
metabolic benefits without undue mitogenic activity.
Similar dissociation between activation of Akt and ERK
has also been observed following INSR activation by the
peptide ligand S597 [39] and in previous studies with anti-
receptor antibodies [40]. The mechanism underlying such
biased agonism is poorly understood, although IRS pro-
teins may be preferentially phosphorylated by plasma
membrane-associated receptor [33, 41], whereas receptor
internalisation is required for full ERK activation [33, 42].
We studied only a limited number of insulin and antibody
concentrations. While these were selected with reference to
prior studies and observed blood insulin concentrations in
insulin receptoropathy, the conditions we describe may not
be most relevant in vivo, where insulin and antibody concen-
trations in the interstitial space of target tissues may be vari-
able and different. Moreover, receptor overexpression may
have partially overcome receptor dysfunction and made ben-
eficial effects of antibody more difficult to observe. Finally, in
Fig. 5 Insulin- and antibody-stimulated glucose uptake via WT and mu-
tant INSR. 3T3-L1 MmINSRKD hINSRWT (a), P193L (b), F248C (c),
R252C (d), S323L (e), F382V (f), D707A (g), P1178L (h) and
MmINSRKD (i) adipocytes were grown in the presence of 1 μg/ml
DOX for 10 days prior to overnight serum starvation on day 15 of differ-
entiation. The cells were stimulated for 30 min with either 10 nmol/l
insulin (red bars), 10 nmol/l antibody (83-7, 83-14 or control IgG; dark
grey bars) or 10 nmol/l insulin containing 10 nmol/l antibody (light grey
bars) prior to the addition of 2-deoxy-D-glucose for 5 min. Cells were then
washed, lysed and assessed for 2-deoxy-D-glucose uptake. Bar chart data
are the mean ± SD from three independent experiments; scatter plots
indicate the mean of triplicates from each independent experiment.
Statistical significance was determined by one-way ANOVA with
Tukey’s multiple comparison test: *p < 0.05, **p < 0.01 and
***p < 0.001, vs unstimulated basal; †p < 0.05, ††p < 0.01 and
†††p < 0.001, vs 10 nmol/l insulin treatment; ‡p < 0.05, ‡‡p < 0.01 and
‡‡‡p < 0.001, vs 10 nmol/l IgG control treatment; §p < 0.05, §§p < 0.01
and §§§p < 0.001, vs 10 nmol/l insulin in the presence of 10 nmol/l IgG
control. 2-DG, 2-deoxy-D-glucose
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the paradigm of acute antibody stimulation with static signal-
ling endpoints, issues such as the potential of long-term anti-
body treatment to downregulate receptors, and the effect of
antibodies on receptor recycling kinetics in vivo have not been
addressed. This is likely to be particularly important for the
subset of mutants (e.g. I119M, K460E) where acute insulin
stimulations studies are normal, as in this and other reports,
but which confer extreme insulin resistance in vivo.
Conclusions
Multiple monoclonal antibodies can bind and activate mutated
cell surface INSR to a potentially clinically significant degree.
Experience in WTanimals [13] and theoretical considerations
argue that effects of anti-INSR antibodies in vivo may be
greater than in cells, so further studies in animal models are
warranted.
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